Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs For Patients Using GIMOTI Over Oral Metoclopramide Presented At The American College Of Gastroenterology 2023
Portfolio Pulse from Benzinga Newsdesk
Evoke Pharma (NASDAQ:EVOK) and EVERSANA have presented real-world data demonstrating that GIMOTI, a nasal spray for treating diabetic gastroparesis (DGP), reduces healthcare costs compared to oral metoclopramide. The data, presented at the American College of Gastroenterology 2023 Annual Meeting, shows that DGP patients treated with GIMOTI were less likely to visit the emergency department or be admitted to the hospital. Over a six-month period, GIMOTI patients spent approximately $15,000 less than those on oral metoclopramide.
October 31, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evoke Pharma's GIMOTI nasal spray has been shown to reduce healthcare costs for diabetic gastroparesis patients, which could potentially increase its market share and revenues.
The real-world data presented shows that GIMOTI reduces healthcare costs compared to oral metoclopramide. This could make GIMOTI a more attractive option for healthcare providers and patients, potentially leading to increased sales and revenues for Evoke Pharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100